Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Camrelizumab |
Anti-PD-1 mAb | Both (Solid & Hematologic) | ||
|
Molecule
Camrelizumab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
||||
Capmatinib |
RET / MET / KRAS / IDH Inhibitor | Solid Tumour | ||
|
Molecule
Capmatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
||||
Carfilzomib |
Proteasome Inhibitor | Hematologic (Multiple Myeloma) | ||
|
Molecule
Carfilzomib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
||||
CC-90009 (Cereblon E3 Ligase Modulator) |
IMiD (Cereblon Modulator) | Hematologic (Multiple Myeloma) | ||
|
Molecule
CC-90009 (Cereblon E3 Ligase Modulator)
Therapeutic Category
Immunomodulatory Agent
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
IMiD (Cereblon Modulator) |
||||
CC-94676 |
Androgen Receptor Degrader (PROTAC) | Solid Tumour (Prostate) | ||
|
Molecule
CC-94676
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
||||
Cediranib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Cediranib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Cemiplimab |
Anti-PD-1 mAb | Both (Solid & Hematologic) | ||
|
Molecule
Cemiplimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
||||
Ceralasertib |
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) | Solid Tumour | ||
|
Molecule
Ceralasertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
||||
Cerdulatinib |
SYK / Multi-Kinase Inhibitor | Hematologic | ||
|
Molecule
Cerdulatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
SYK / Multi-Kinase Inhibitor |
||||
Ceritinib |
ALK / ROS1 / NTRK Inhibitor | Solid Tumour | ||
|
Molecule
Ceritinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
||||
Cevostamab |
Bispecific T-Cell Engager | Both (Solid & Hematologic) | ||
|
Molecule
Cevostamab
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
||||
Chidamide |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Chidamide
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
CamrelizumabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
|
CapmatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
|
CarfilzomibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
|
CC-90009 (Cereblon E3 Ligase Modulator)Immunomodulatory Agent |
|
|
Therapeutic Category
Immunomodulatory Agent
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
IMiD (Cereblon Modulator) |
|
CC-94676Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
|
CediranibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
CemiplimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
|
CeralasertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
|
CerdulatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
SYK / Multi-Kinase Inhibitor |
|
CeritinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
|
CevostamabImmunotherapy (Bispecific Antibody) |
|
|
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
|
ChidamideTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|